- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03898856
Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
May 15, 2023 updated by: Brooks Cash, The University of Texas Health Science Center, Houston
Yield of Diagnostic Tests and Management of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients: A Pilot Study
The purpose of this study is to evaluate the effectiveness of the drug Crofelemer in the treatment of non-HIV patients with chronic idiopathic diarrhea; to determine the prevalence of identifiable causes of chronic diarrhea in a non-HIV patients; to assess the diagnostic yield, in terms of identification of treatable etiologies, of commercially available diagnostic evaluations in adult, non-HIV patients with chronic idiopathic diarrhea, that is, evaluate which tests, among the standard diagnostic tests commonly conducted as part of the evaluation of chronic idiopathic diarrhea, are most likely to identify a treatable cause of the diarrhea; and to analyze the relationship between chronic idiopathic diarrhea and health-related quality of life and assess the impact of crofelemer treatment on health-related quality of life.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Brooks Cash, MD
- Phone Number: 713-500-6677
- Email: Brooks.D.Cash@uth.tmc.edu
Study Contact Backup
- Name: Brooks Cash, MD
- Email: gi.research@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas health Science Center at Houston
-
Contact:
- Brooks Cash, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with chronic diarrhea (defined as 3 non-bloody loose stools per day or more than 20 non-bloody loose stools per week for more ≥ 4 weeks) and Bristol Stool Form Scale for stool consistency of 6/7 with >50% stool without an obvious cause after evaluation for organic etiologies.
- Patients from any ethnicity
Exclusion Criteria:
- Hematochezia (potentially related to an organic cause).
- Subjects less than 18 years of age more than 75 years of age (safety and effectiveness of crofelemer has not been established in these age groups).
- Pregnant females (crofelemer is a Category C drug due to lack of well-controlled studies to study its effects in this population).
- Lactating females (it is unknown if crofelemer is excreted in the human milk and thus may have unknown adverse effects on the nursing infants).
- HIV positive individuals.
- Persons within ability to provide consent and understand the study
- Persons with history of alcohol abuse or binge drinking.
- Persons with history of surgical bowel resection or bariatric surgery in the past 12 months.
- Persons who have undergone cholecystectomy (open or laparoscopic) in the past 3 months.
- Persons receiving antibiotics currently or have received antimicrobials in the past 4 weeks.
- Persons with end-organ failures including end-stage renal disease, end-stage liver disease, or severe heart failure.
- Persons with metastatic hematologic and oncologic malignancies.
- Persons receiving chemo-radiation or immune-modulators for oncologic or rheumatologic conditions.
- Persons with any other known organic gastrointestinal or non-gastrointestinal disease process in which diarrhea is a recognized clinical feature.
- Gluten free diet for previous 3 months and refusal to ingest gluten.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Crofelemer and Diagnostic tests for cause of chronic diarrhea
125 mg tablets taken by mouth twice daily for 28 days
|
125 mg tablets taken by mouth twice daily for 28 days
Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with a 50 percent decrease in mean stool count per week
Time Frame: Week 4
|
Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with an improvement in stool consistency by more than 2 levels as measured by the Bristol stool form scale
Time Frame: week 4
|
The Bristol stool form scale is a validated 1-7 scale that correlates to stool form.
Type 1 is pebble like stool, type 2 lumpy and hard, type 3 like a sausage with cracks on the surface type 4 like a sausage but smooth and soft, type 5 soft blobs with clear cut edges, type 6 fluffy pieces with ragged edges, mushy stool, type 7watery, no solid pieces Types 5-7 are consistent with diarrhea and for this study a movement to lower types is considered an improvement
|
week 4
|
Change in physical, psychological, and social functioning as measured by the Health-related quality of life (HRQOL) questionnaire
Time Frame: Baseline,week 4 of treatment
|
The Medical Outcomes Trust short form questionnaire with 36 questions, most often referred to as SF-36, is a measure of general health status relevant across age, disease and treatment groups, widely used and tested in a range of conditions and settings.
The items in SF-36 are divided into eight different domains with overall physical and mental health component summary scores.
Domains are physical functioning, role limitations physical, bodily pain, social functioning, general mental health, role limitations emotional, vitality and general health.
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
|
Baseline,week 4 of treatment
|
Number of participants with any abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Esophagogastroduodenoscopy
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Colonoscopy
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Biopsy of duodenum
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Biopsy of Colon
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Prometheus IBcause Chronic Diarrhea panel
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Thyroid Function Tests
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Stool osmolality
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Stool Ova and Parasites
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Stool Culture
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Stool Qualitative Stool Fat
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Stool Reducing Substances
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Laxative Screening
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Lactulose Hydrogen Breath Test
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-Gastrin Level
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-. Calcitonin Level
Time Frame: Baseline
|
Baseline
|
|
Number of participants with abnormal diagnostic test results leading to the identification of the cause of chronic diarrhea-VIP Level
Time Frame: Baseline
|
Baseline
|
|
Change in participant diary descriptors as measured by time of bowel movements per 24 hr period
Time Frame: Baseline,week 4 of treatment
|
Baseline,week 4 of treatment
|
|
Change in participant diary descriptors as measured by number of loose stools per 24 hr period
Time Frame: Baseline,week 4 of treatment
|
Baseline,week 4 of treatment
|
|
Change in participant diary descriptors as measured by consistency of each bowel movement as per the Bristol Stool Form Scale
Time Frame: Baseline,week 4 of treatment
|
The Bristol stool form scale is a validated 1-7 scale that correlates to stool form.
Type 1 is pebble like stool, type 2 lumpy and hard, type 3 like a sausage with cracks on the surface type 4 like a sausage but smooth and soft, type 5 soft blobs with clear cut edges, type 6 fluffy pieces with ragged edges, mushy stool, type 7watery, no solid pieces Types 5-7 are consistent with diarrhea and for this study a movement to lower types is considered an improvement
|
Baseline,week 4 of treatment
|
Change in participant diary descriptors as measured by the presence of urgency with each bowel movement
Time Frame: Baseline,week 4 of treatment
|
0-4 visual analog scale (0=none; 4=incontinence)
|
Baseline,week 4 of treatment
|
Change in participant diary descriptors as measured by supportive anti-diarrheal medication taken
Time Frame: Baseline,week 4 of treatment
|
Yes or no
|
Baseline,week 4 of treatment
|
Change in participant diary descriptors as measured by dose of supportive anti-diarrheal medication taken
Time Frame: Baseline,week 4 of treatment
|
Baseline,week 4 of treatment
|
|
Change in participant diary descriptors as measured by number of anti-diarrheal medication taken per 24-hr period
Time Frame: Baseline,week 4 of treatment
|
Baseline,week 4 of treatment
|
|
Change in participant diary descriptor of daily time of administration of crofelemer
Time Frame: Baseline,week 4 of treatment
|
Time
|
Baseline,week 4 of treatment
|
Change in participant diary descriptor of any new symptoms
Time Frame: Baseline,week 4 of treatment
|
Baseline,week 4 of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Brooks Cash, MD, The University of Texas Health Sciences Center at Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2019
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
December 31, 2023
Study Registration Dates
First Submitted
March 29, 2019
First Submitted That Met QC Criteria
March 29, 2019
First Posted (Actual)
April 2, 2019
Study Record Updates
Last Update Posted (Actual)
May 17, 2023
Last Update Submitted That Met QC Criteria
May 15, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-18-0990
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Diarrhea of Unknown Origin
-
IpsenCompletedChronic Functional Diarrhea of Unknown OriginNetherlands, United Kingdom
-
Assistance Publique Hopitaux De MarseilleUnknownAntibiotic Resistant Infection | Clostridium Difficile | Chronic Diarrhea of Unknown OriginFrance
-
Keymed Biosciences Co.LtdNot yet recruitingChronic Pruritus of Unknown Origin
-
Universitair Ziekenhuis BrusselRecruiting
-
University Hospital, MontpellierCompletedFever of Unknown OriginFrance
-
Sohag UniversityRecruitingMetastasis of Unknown OriginEgypt
-
Carina Mari ApariciWithdrawnFever of Unknown OriginUnited States
-
University Hospital, GrenobleCompletedFever of Unknown OriginFrance
-
Tongji HospitalUnknownFever of Unknown OriginChina
Clinical Trials on Crofelemer
-
Shaman PharmaceuticalsCompleted
-
Bausch Health Americas, Inc.CompletedHIV Associated DiarrheaUnited States, Puerto Rico
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.CompletedHIV Enteropathy | Diarrhea With HIVUnited States
-
Bausch Health Americas, Inc.CompletedIrritable Bowel Syndrome | Colonic Diseases | Diarrhea | Gastrointestinal DiseaseUnited States
-
Beth Israel Deaconess Medical CenterTerminated
-
Napo Pharmaceuticals, Inc.Active, not recruitingAdult Solid Tumor | Cancer Therapy-Related Diarrhea | Chemotherapy-related Diarrhea | Prophylaxis of Diarrhea | Symptomatic Relief of Diarrhea | Targeted Therapy-related DiarrheaUnited States, Taiwan, Georgia, Serbia, Argentina
-
Sandra SwainGenentech, Inc.; Medstar Health Research Institute; Lombardi Comprehensive Cancer... and other collaboratorsCompletedDiarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients (HALT-D)Breast CancerUnited States
-
Shaman PharmaceuticalsCompletedHIV Infections | Herpes SimplexUnited States
-
Lindsey Russell, MDNapo Pharmaceuticals, Inc.Not yet recruitingShort Bowel SyndromeUnited States